LOS ANGELES--(EON: Enhanced Online News)--Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Regulus Therapeutics Inc. (“Regulus” or the “Company”) (Nasdaq: RGLS) concerning possible violations of federal securities laws.
Regulus revealed that it was contacted by the U.S. Food and Drug Administration ("FDA") that its new drug against the chronic hepatitis C virus infection will be placed on clinical hold due to another incidence of jaundice.
On January 27, 2017, Regulus disclosed that the FDA would not remove the clinical hold on RG-101 until the agency confirms the last safety and efficacy information from continued clinical and pre-clinical studies.
When this information was revealed to the investing public, shares of Regulus fell sharply, causing investors harm.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.